Better Physical and Mental Health Following Rebyota Treatment for CDI

Ferring Pharmaceuticals has unveiled new real-world data analyses for Rebyota (fecal microbiota, live – jslm) at the American College of Gastroenterology (ACG) 2024 annual meeting. These analyses demonstrate Rebyota's effectiveness in patients with gastrointestinal conditions, whether treated at home or in clinical settings, contributing to the expanding evidence supporting its use.

Among the three analyses presented, the third focused on patients' health-related quality of life (HRQoL) from a Phase 3b clinical trial. Preliminary data from 15 interviews indicated significant post-treatment improvements, with 73.3% of patients reporting enhanced physical function and 86.7% experiencing better mental well-being.

In this interim analysis, participants from the CDI-SCOPE clinical trial were interviewed to assess the burden of recurrent Clostridioides difficile infection (CDI) on HRQoL and to identify improvements after Rebyota administration.

Patient Symptoms: Before treatment, 66.7% of patients reported diarrhea as their most bothersome symptom, with 70% emphasizing its resolution as crucial.

Post-Treatment Outcomes: After receiving Rebyota, 53.3% of participants reported complete resolution of diarrhea, while 46.7% noted reduced severity, with average symptom severity ratings decreasing from 8.4 to .3 on a scale of 0-10.

Impact on Daily Life: CDI significantly disrupted daily activities, with 80% of patients needing to stay close to a bathroom, impacting leisure time (80%), sleep (73.3%), and nutrition (73.3%). Additionally, 60% expressed concerns about the recurrence of CDI and reported debilitating fatigue.

Improvements After Rebyota: Following treatment, patients noted improvements in physical function (73.3%), family interactions (93.3%), leisure activities (73.3%), and overall mental health (86.7%).

Rebyota is FDA-approved for preventing recurrent CDI in adults following antibiotic treatment. The therapy comprises a microbiota suspension administered rectally, delivering trillions of live microbes directly to the gut. CDI presents a significant healthcare challenge, with high recurrence rates after initial treatment. Ferring's analyses underscore Rebyota 's potential to improve clinical outcomes and enhance the quality of life for patients suffering from this debilitating condition. These findings highlight Rebyota 's role in addressing clinical symptoms and the overall quality of life in patients with recurrent CDI, supporting its efficacy and safety in real-world settings.

Learn more about Rebyota’s success in different clinical studies: A Clinician’s Perspective on REBYOTA for Recurrent C. Diff Treatment

Reference

Ferring Presents New Data Analyses for REBYOTA® (fecal microbiota, live – jslm) at ACG 2024. Ferring. October 28, 2024. Accessed October 28, 2024. https://ferringusa.com/?press=ferring-presents-new-data-analyses-for-rebyota-fecal-microbiota-live-jslm-at-acg-2024